A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657-K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Trial Profile

A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657-K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Fimasartan (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Boryung
  • Most Recent Events

    • 30 Jun 2016 Status changed from recruiting to completed.
    • 24 Aug 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01672476).
    • 24 Aug 2012 Planned End Date 1 Mar 2013 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top